Liquidia Corporation (LQDA)
NASDAQ · Healthcare
$77.08-3.58%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $7.07B
- P/E ratio
- —
- EPS
- —
- Volume
- 1,012,828
- 52-week high
- —
- 52-week low
- —
- Open
- $79.96
- Day high
- $81.42
- Day low
- $76.98
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $158.32M | -$68.92M | -$0.80 |
| 2024 | $14M | -$128.29M | -$1.63 |
| 2023 | $17.49M | -$78.5M | -$1.21 |
| 2022 | $15.94M | -$41.02M | -$0.67 |
| 2021 | $12.85M | -$34.58M | -$0.70 |
About Liquidia Corporation
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
- CEO
- Roger A. Jeffs
- Employees
- 216
- Country
- US
- IPO date
- Jul 26, 2018
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Liquidia Corporation's stock price today?
- LQDA is trading at $77.08 as of Jul 20, 2026.
- What is Liquidia Corporation's market cap?
- Liquidia Corporation (LQDA) has a market capitalization of $7.07B.
- Does Liquidia Corporation pay a dividend?
- Liquidia Corporation did not pay a dividend in its most recent reported fiscal year.
- What sector is Liquidia Corporation in?
- Liquidia Corporation operates in the Healthcare sector.